BARRIER ACQUIRES CANADIAN RIGHTS FOR VANIQA

Barrier Therapeutics, a pharmaceutical company developing products in the field of dermatology, announced that it has acquired the right to distribute Vaniqa (eflornithine hydrochloride) Cream, 13.9 percent in Canada from Shire Pharmaceutical Contracts Limited. Vaniqa is currently the only prescription product approved by Health Canada for slowing the growth of unwanted facial hair in women. Under the terms of the agreement, Barrier will be the exclusive distributor for Vaniqa in the Canadian territory and will be responsible for all sales, marketing, regulatory and distribution activities.

Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=89348)